Browse studies

Find your next paid study

5 recruiting studies matching your filters

A Phase 1/2 Trial of RPTR-1-201, a T Cell Receptor Bispecific Therapy, in Advanced Solid Tumors

This is an early phase trial designed to evaluate the safety, tolerability, and preliminary antitumor activity of RPTR-1-201 in adults with advanced solid tumo…

Advanced Malignant Solid Tumor

Estimated

~$10 – $7,500

Repertoire Immune MedicinesNCT07293754

Phase 1

A Phase 1 Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLT012 in Patients With Advanced Solid Tumors

The goal of this clinical trial is to learn about what doses of PLT012 are safe to use in adults with advanced cancers in solid tumors. It will also learn abou…

Advanced Malignant Solid TumorSolid Tumor Cancer

Estimated

~$10 – $8,750

Pilatus Biosciences IncNCT07337525

Phase 1

Phase 1a/1b Study of CT-95 in Advanced Cancers Associated With Mesothelin Expression

This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamic…

Mesothelin-Expressing TumorsEpithelial Ovarian CancerMalignant Pleural Mesothelioma, Advanced+8 more

Estimated

~$10 – $8,750

Context Therapeutics Inc.NCT06756035

Phase 1

A Phase 1, Single-Arm, Open-Label, Dose-Escalation, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CS231295 in Patients With Advanced Solid Malignant Tumors

This is a Phase I, single-arm, open-label, dose-escalation, multicenter clinical study of CS231295 in patients with advanced solid malignant tumors. Eligible …

Advance Solid TumorsAdvanced Malignant Solid Tumors

Estimated

~$10 – $8,750

ThalassaX Therapeutics United States LtdNCT07612488

Phase 1

A Phase I/IIA Study Evaluating the Safety and Efficacy of NY-ESO-1TCR/dnTGFBRII Engineered T Cells in Combination With Decitabine in Subjects With Recurrent or Treatment Refractory Ovarian Cancer and Other Advanced Malignancies

This phase I/IIA trial studies the side effects and best dose of gene-modified T cells when given with or without decitabine, and to see how well they work in …

Ovarian CancerAdvanced Malignant Solid Tumor

Estimated

~$10 – $6,250

University of ChicagoNCT07389239